Abeona Therapeutics (ABEO) Cash & Equivalents (2010 - 2026)

Abeona Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $61.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 285.13% year-over-year to $61.4 million; the TTM figure through Mar 2026 stood at $61.4 million (up 285.13% YoY), while the FY2025 annual figure was $78.4 million, up 231.03% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $61.4 million, down from $78.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $163.5 million in Q2 2025, with the low at $338000.0 in Q1 2023.
• The 5-year median for Cash & Equivalents is $14.6 million (2022), against an average of $29.5 million.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents slumped 94.85% in 2024, then jumped 48283.14% in 2025.
• Abeona Therapeutics' Cash & Equivalents stood at $14.6 million in 2022, then advanced by 1.76% to $14.8 million in 2023, then surged by 59.98% to $23.7 million in 2024, then jumped by 231.03% to $78.4 million in 2025, then declined by 21.75% to $61.4 million in 2026.
• Business Quant data shows ABEO's Cash & Equivalents at $61.4 million in Q1 2026, $78.4 million in Q4 2025, and $83.2 million in Q3 2025.